Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Liquidia Corp (LQDA)

Liquidia Corp (LQDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 153,326
  • Shares Outstanding, K 51,975
  • Annual Sales, $ 740 K
  • Annual Income, $ -59,760 K
  • 60-Month Beta 0.08
  • Price/Sales 201.58
  • Price/Cash Flow N/A
  • Price/Book 1.58
Trade LQDA with:

Options Overview Details

View History
  • Implied Volatility 106.38%
  • Historical Volatility 43.12%
  • IV Percentile 41%
  • IV Rank 24.87%
  • IV High 211.56% on 10/27/20
  • IV Low 71.55% on 05/27/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 154
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,035
  • Open Int (30-Day) 1,975

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.12
  • Number of Estimates 3
  • High Estimate -0.06
  • Low Estimate -0.15
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +70.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.52 +15.48%
on 09/21/21
3.00 -3.00%
on 09/27/21
+0.21 (+7.78%)
since 08/27/21
3-Month
2.25 +29.33%
on 08/06/21
3.00 -3.00%
on 09/27/21
-0.01 (-0.34%)
since 06/28/21
52-Week
2.25 +29.33%
on 08/06/21
5.95 -51.09%
on 10/12/20
-1.84 (-38.74%)
since 09/28/20

Most Recent Stories

More News
Liquidia to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

Liquidia Corporation (NASDAQ: LQDA) announced today that Damian deGoa, Chief Executive Officer, will present at the H.C. Wainwright 23 Annual Global Investment Conference, which runs from September 13...

LQDA : 2.91 (-1.36%)
U.S. Patent Trial and Trademark Appeal Board Decides to Institute Inter Partes Review of United Therapeutics' Tyvaso(R) Patent

Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) against U.S. Patent No. 10,716,793 ('793 patent), owned by...

UTHR : 187.66 (-3.90%)
LQDA : 2.91 (-1.36%)
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 18.75% and 95.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?...

LQDA : 2.91 (-1.36%)
United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia

and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, Inc. (a subsidiary...

LQDA : 2.91 (-1.36%)
UTHR : 187.66 (-3.90%)
Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder

Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for LIQ861 (treprostinil) inhalation powder...

UTHR : 187.66 (-3.90%)
LQDA : 2.91 (-1.36%)
Liquidia Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration

Liquidia Corporation (NASDAQ: LQDA) ("Liquidia" or the "Company") today announced that Sandoz Treprostinil Injection, a generic form of Remodulin(R), is now also available for subcutaneous ("SC") administration...

LQDA : 2.91 (-1.36%)
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -5.00% and 260.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?...

LQDA : 2.91 (-1.36%)
Rising P/E: An Overlooked Way to Pick 5 Winning Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

CPRT : 141.14 (-3.80%)
NBRV : 1.1900 (-5.56%)
ALYA : 2.49 (-2.73%)
LQDA : 2.91 (-1.36%)
CRDF : 7.10 (-3.92%)
Liquidia Corporation Announces $21.7 Million Private Placement

Liquidia Corporation (NASDAQ: LQDA) announced today that it has entered into a common stock purchase agreement with certain institutional, accredited investors for the private placement of 8,626,037 shares...

AMAG : 13.75 (+0.15%)
MS : 102.04 (-2.91%)
LQDA : 2.91 (-1.36%)
Vyant Bio Announces Newly Appointed Board of Directors

Vyant Bio, Inc. (the "Company") (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery of...

VYNT : 2.37 (+1.28%)
KYMR : 60.82 (-4.36%)
NANO : 35.33 (-0.81%)
LQDA : 2.91 (-1.36%)
IDRA : 1.0600 (-1.85%)
SNDX : 19.51 (-1.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of...

See More

Key Turning Points

3rd Resistance Point 3.10
2nd Resistance Point 3.04
1st Resistance Point 2.98
Last Price 2.91
1st Support Level 2.86
2nd Support Level 2.80
3rd Support Level 2.74

See More

52-Week High 5.95
Fibonacci 61.8% 4.54
Fibonacci 50% 4.10
Fibonacci 38.2% 3.66
Last Price 2.91
52-Week Low 2.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar